HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin Therapy Lowers Stroke Risk In Women, MI Risk In Men – JAMA

This article was originally published in The Tan Sheet

Executive Summary

A recent meta-analysis identifying aspirin's cardiovascular benefits as gender-specific may demonstrate that primary prevention benefits extend to low-risk groups

You may also be interested in...



Aspirin counseling

AMA adopts a policy to increase physician education on the importance of appropriately counseling patients on aspirin therapy for prevention of heart disease and stroke, according to a separate release from the associations' annual meeting in Chicago. Six trials involving more than 95,000 adults using aspirin demonstrate the potential cardiovascular benefits of aspirin. Trial results show a 17 percent reduced risk of stroke in women and a 32 percent reduced risk of myocardial infarction in men (1"The Tan Sheet" Jan. 23, 2006, p. 7)...

Aspirin Suppresses Platelet Aggregation In Both Women, Men – JAMA

Findings from a study on gender-specific responses to aspirin treatment suggest that low-dose aspirin therapy is beneficial for both men and women in improving cardiovascular health

Aspirin MI Primary Prevention Labeling Urged In Bayer Citizen Petition

Aspirin therapy led to a statistically significant 32% reduction in first myocardial infarctions among over 55,000 subjects evaluated in a meta-analysis of five primary prevention studies conducted by Bayer Consumer Care

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel